Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LOL!!!
So what? IT'S NOT ABOUT JT ANY MORE!!! It's only about $$$NSAV$$ and JT will disappear soon IMHO.
We should be 20 C by now! $$$NSAV$$$
Are we still under 5 C? Incredible. $$$NSAV$$$
Good day for NSAVers and better days are coming!
4 C would be super for today but doesn't look like it. Needs more volume for it. $$$NSAV$$$
Lets finish with paper money by Friday ... LOL.
Thank you TheAmbassador for posting. GLTY.
Halberd and GTX Corp. Sign Scientific Collaboration and Reseller Agreement
Press Release | 10/12/2021
GTX and Halberd will begin collaborating on developing and testing treatments for Alzheimer's Disease/PTSD and other neurological diseases and GTX will begin marketing Halberd's VitaShieldMaxTM Immune Support through their online ecommerce platform.
JACKSON CENTER, PA / ACCESSWIRE / October 12, 2021 / Halberd Corporation (OTC PINK:HALB) and GTX Corp. (OTC PINK:GTXO) have agreed to work together on various neurodegenerative diseases such as Alzheimer's Disease, Parkinson's Disease, PTSD/CTE (Chronic Traumatic Encephalopathy)/ Traumatic Brain Injury), among others. These diseases are prevalent among seniors, active duty and veteran soldiers, participants in contact sports and millions of people in the general population. Halberd and GTX intend to work together to utilize their combined technologies and years of experience in the field to develop superior diagnostics/treatments for these diseases and afflictions.
Additionally, GTX has agreed to sell Halberd's Vita-Shield-MaxTM Immune Support nutraceutical which helps maximize one's natural immunity defenses and will be available on GTX's e-commerce website. Vita-Shield-MaxTM is also available for purchase through Halberd's website, www.vitashieldmax.com, as well as through Amazon.
GTX Corp CEO, Patrick Bertagna, stated: "A sizeable percentage of our customer base is afflicted with Alzheimer's, dementia, autism and traumatic brain injury, and we also work with the military, so we are excited to embark on this project with Halberd to further assist in the development and testing of these unique treatments and solutions for neurodegenerative diseases, along with becoming a reseller of their immune support nutraceutical, Vita-Shield- Max for this large global audience. Our health & safety wearable technology platform has been used in clinical trials by George Mason University's College of Health and Human Services and the Milken Institute School of Public Health at the George Washington University, hence we look to bring some of our experience into this new partnership."
William A. Hartman, Chairman, President and CEO of Halberd Corporation, stated "This agreement provides us a great opportunity to utilize GTX's existing telemetry/ telecommunications systems in addition to our revolutionary medical treatment technology being developed in conjunction with our university research partners. The combination of the two companies' technologies will provide an opportunity to explore potential breakthrough product innovations in biomedical treatment and mobile monitoring of effectiveness.
To get the latest news on Halberd's exciting medical developments, including our ongoing disease eradication accomplishments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com;
support@halberdcorporation.com
http://www.halberdcorporation.com
Twitter:@HalberdC
About GTX Corp.
GTX Corp (OTC PINK:GTXO) is a pioneer in smart, mobile and wearable GPS tracking and recovery location-based solutions, supported through a proprietary IoT enterprise monitoring platform and intellectual property portfolio. GTX offers a global end-to-end solution of hardware, software and connectivity and develops two-way GPS tracking technologies, which seamlessly integrate with consumer products and enterprise applications. GTX utilizes the latest in miniaturized, low power consumption GPS, Cellular, RF, NFC and BLE technology, enabling subscribers to track in real time the whereabouts of people or high value assets. GTX is known for its game-changing and award-winning patented GPS SmartSole® -- the world's first invisible wearable technology tracking device created for those at risk of wandering due to Alzheimer's, dementia, autism and traumatic brain injury. GTX's business model is built around technology innovation and holds over 85 patents, with many issued patents in the area of GPS tracking. The company has international distributors servicing customers in over 35 countries and is a U.S. Military Government contractor. Other customers include public health authorities and municipalities, emergency and law enforcement, private schools, assisted living facilities, NGOs, small business enterprises, senior care homes, and consumers.
GTXCorp.com
Track My Workforce
GPS SmartSole.com
About Halberd Corporation.
Halberd Corporation (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. It holds the exclusive worldwide rights to several patent- and PCT-pending extracorporeal treatments for COVID-19 and other medical maladies: Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287 and an allowed but not yet issued patent for the treatment of Cockayne Syndrome
https://www.otcmarkets.com/stock/HALB/news/Halberds-VITASHIELDMAXTM-Immunity-Support-Product-Available-on-Amazon?id=323723
Sorry my man, you are still not getting it. Welcome to the real $$$NSAV$$$!
Good news are immanent and soon. $$$NSAV$$$
BUDDIK this is $$$NSAV$$$. Watch and learn.
Dollar by Wednesday? LOL.
And no news as promised. JT's BS.
Yes Bonus, you are THE MAN! Thanks for posting. GLTY>
New to The Street / Newsmax T.V. Announces 8 Interviews for this Week's T.V. Broadcast, October 10, 2021, airing at 10-11 AM ET
October 08, 2021 13:30 ET | Source: FMW Media Works Corp
...
NEW YORK, Oct. 08, 2021 (GLOBE NEWSWIRE) -- FMW Media's New to The Street / Newsmax T.V. announces the broadcasting line-up of its national syndicated 1-hour T.V. show this Sunday, October 10, 2021, airing time 10-11 AM ET.
New to The Street's 245th T.V. show line-up features 8 interviews of the Companies and their business' representatives starting with:
1). heliosDX's, a RushNet, Inc. subsidiary (OTCPINK: RSHN), interviews with Mr. Ashley Sweat, CEO, and Mr. Yann Gervill-Reache, COO.
New to The Street T.V. welcomes on this week's show, RushNet, Inc. subsidiary (OTCPINK: RSHN), heliosDX's Mr. Ashley Sweat, Chief Executive Officer, and Mr. Yann Gervill-Reache, Chief Operations Officer. Both Company's executives talk, in-studio at NASDAQ, to the New to The Street T.V. host, Jane King, about heliosDX's high complexity medical and drug testing lab. The focus remains comprehensive in providing patients and medical providers with a brand-name laboratory for testing alternatives with speed and accuracy to that of the big national lab. With a dedicated team at heliosDX, providing high-quality lab services with promptness and integrity, Mr. Sweat, CEO, explains the roadmap on corporate expectations for the next 15-month. He talks about a pending closing on a Reg A+ financing and explains the use-of-proceeds to grow themselves through further acquisitions. The Company's objective is to become a national brand-name, recognizable lab facility. Mr. Yann Gervill-Reache, COO, gives the viewers an overview of what it will take for the Company to become a national lab and the numerous compliance strategies needed on state and federal levels.
https://www.globenewswire.com/news-release/2021/10/08/2311349/0/en/New-to-The-Street-Newsmax-T-V-Announces-8-Interviews-for-this-Week-s-T-V-Broadcast-October-10-2021-airing-at-10-11-AM-ET.html
JT is not a major player any more regardless of his title. In the company running by Chinese who doesn't have good English he is just needed at this time, but I personally have nothing against him.
$$$NSAV$$$ is ones in a life time opportunity here and is going to be huge IMHO, but each shareholder has to be able to see that and it is not so difficult to do. GLTA.
$$$NSAV$$$. Have a good night all NSAVers.
My conclusion about JT that he is not in the circle and doesn't know much. He hears the bells but doesn't know where is it coming from.
JT it's time to say something more to shareholders. NO MORE GAMES!!!
Buys over Sells 2:1. $$$NSAV$$$
And under 3's are moving fast. $$$NSAV$$$
Thank you Bonus for the GREAT $$$NSAV$$$ NEWS!
NSAV is moving on great news!
Buying small, but still buying. $NSAV$
Thank you Stockmanjr, SUPER!
Halberd Corporation CEO Letter
Press Release | 10/07/2021
Jackson Center, Pennsylvania--(Newsfile Corp. - October 7, 2021) - Greetings From The CEO And Staff At HALBERD CORPORATION! (OTC PINK: HALB)
This past quarter, Halberd has made some very significant and unparalleled achievements developing treatments for neurodegenerative diseases, such as PTSD/ CTE (Post Traumatic Stress Disorder/Chronic Traumatic Encephalopathy), Alzheimer's Disease, Parkinson's Disease, etc.
As reported in the last quarterly update, our research led us to investigate RF (Radio Frequency) and laser exposure, as the two patent-pending extracorporeal methods to eliminate targeted disease antigens. Our results this past quarter have been successful beyond our expectations. Our patented methodology has successfully eliminated Phosphorylated Tau from CSF (Cerebral Spinal Fluid). Phosphorylated Tau is believed to be the principal contributor to neurofibrillary tangles linked to Alzheimer's Disease related cognitive degeneration. Our scientists and research partners are confident that by eliminating this antigen, which we have accomplished in vitro, cognitive degeneration will be reduced, if not eliminated. Due to our laboratory success in eradicating Phosphorylated Tau, we are confident we will be successful in eliminating the remaining similar-sized target antigens and inflammatory cytokines linked to Alzheimer's Disease.
Halberd, through its research partner, Youngstown State University (YSU), successfully eliminated E.coli from buffer solution through RF and separately through laser radiation. This work continues, and will be expanding in the fourth quarter to evaluate elimination from bodily fluids. E.coli's presence in CSF is responsible for meningitis, and E.coli in blood is responsible for blood sepsis. Combined, these two afflictions are responsible for the deaths of an estimated 750,000 people each year in the US alone. Our scientists and research partners target the elimination of such deaths through our patented methodology.
In dealing with each disease state, we carefully calibrate the RF generator as well as the laser frequency regarding factors such as temperature, time exposure, particle size and other factors in order to ensure elimination of each disease antigen. Additionally, in each calibration, often disease specific, our scientists adjust the number of antibodies vis-à-vis antigens to determine the ideal eradication calibration.
With each success, we move closer to our goal -- universal disease eradication through our patented extracorporeal methodology.
Our work in the coming quarter will center on elimination of the remaining antigens and inflammatory cytokines associated with the above neurodegenerative diseases and other diseases. As in other industries, our continuing work has been plagued by ongoing supply shortages, resulting in long delays of our planned research and development. We will continue to strive to address these shortages and move to mitigate delays.
STOCK PERFORMANCE
Halberd's fiscal year concluded July 31, 2021. Documentation for the periods prior to the placement of the current management team delayed submission of the appropriate material to the auditors until mid-September 2021. Recent SEC/FINRA actions to delist non-reporting companies have caused a huge demand for auditor services, thereby delaying approval of our financial package. We are doing everything possible to move this along and up-list to OTCQB. The Form 10 drafting has been sourced to an attorney and will be completed once the audit concludes. Listing on additional stock exchanges will be considered once we complete the up-listing on OTCQB.
Q3 OBJECTIVES AND ACCOMPLISHMENTS RECAP
Establish proof-of concept for eradication of E. Coli via RF and laser as the initial steps toward development of an Alzheimer's Disease treatment.
Proof of concept established.
Conduct further laboratory development, fine tuning, and demonstration of the effectiveness of our application of the extracorporeal capture and removal of disease antigens without the need for metallic nanoparticles. (Details to be provided pending patent application filings).
Dedicated prototypes are in the process of manufacture, but testing has been replaced by the ongoing and very promising laser and RF eradication of neurodegenerative disease antigens.
Launch immune support product to the market.
Launched Vita-Shield-MaxTM Immune Support product on our website, www.vitashieldmax.com, and on Amazon.
Complete application for up-listing HALB to OTCQB index.
Pending audit approval.
Complete application for Halberd Corp.'s listing on one of the Canadian stock exchanges.
Pending audit approval and up-listing to OTCQB.
Q4 OBJECTIVES
Successfully eradicate the inflammatory cytokines, IL-6 and TNF-alpha, from Cerebral Spinal Fluid. These two cytokines are believed to be the principal causation of suicide ideation associated with PTSD.
Presentations to the NFL, DARPA and the military outlining our achievements in elimination of the inflammatory cytokines believed to be associated with suicide ideation and PTSD and seek their support/endorsement/participation in and for our continuing study.
Continue efforts to successfully eradicate other identified antigens and inflammatory cytokines associated with Alzheimer's Disease, Parkinson's Disease, etc.
Continue to strengthen our Intellectual Property position through additional provisional patent applications and conversion of past provisional applications into patent applications and patents. NOTE_ Halberd Corporation has three existing patents and has filed eleven provisional patent applications to date. Our continuing strategy is to aggressively develop intellectual property.
Continue to expand the number and breadth of scientific experts on Halberd's team to enhance our successes in the future.
SUMMARY
Halberd continues to strive to deliver maximum value to our shareholders by focusing on the prominent health issues not adequately addressed by other biomedical or pharmaceutical interests. Our current focus on developing treatments for PTSD, CTE, and Alzheimer's Disease reflects that commitment. Since 9/11, four times as many military personnel have committed suicide than have been killed in combat. Careers in contact sports have also produced alarming numbers of suicides associated with neurodegenerative diseases. Alzheimer's Disease is reportedly the seventh leading cause of death in the US.
We believe that Halberd's scientists, using our technology and expertise, are equipped to develop successful treatments for these neurodegenerative diseases which plague our military, professional athletes and our people in general.
Sincerely,
William A. Hartman
Chairman, President & CEO
HALBERD CORPORATION
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter:@HalberdC
To get the latest news on Halberd's exciting developments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)
About Halberd Corporation.
Halberd Corporation (OTC Pink: HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. It holds the exclusive worldwide rights to several patent- and PCT-pending extracorporeal treatments for COVID-19 and other medical maladies: Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287and an allowed but not yet issued patent for the treatment of Cockayne Syndrome.
https://www.otcmarkets.com/stock/HALB/news/Halberd-Corporation-CEO-Letter?id=324229
To whoever doubted about today's PR it's here. $NSAV$
But it is not trading according to E*Trade. What should I do?
I hope they'll tested before this time. Also we should be getting PR prior to that on other news IMO. GLTA.
Halberd's VITASHIELDMAX(TM) Immunity Support Product Available on Amazon
Press Release | 10/05/2021
Jackson Center, Pennsylvania--(Newsfile Corp. - October 5, 2021) - Halberd Corporation (OTC Pink: HALB) announced that its nutraceutical immune support product, VitaShieldMaxTM, is now available through Amazon, in addition to its availability through Halberd's website at www.vitashieldmax.com.
William A. Hartman, Halberd's Chairman, President & CEO, stated, "We are pleased that our product will now also be available through Amazon, and will be able to reach virtually anyone in need of immunity support to maintain their body's health and resistance to diseases. Halberd's scientists carefully formulated VitaShieldMaxTM ingredients to support key immune system needs. References supporting ingredient selection can be found in a 120-page compilation of numerous medical articles on Halberd's website."
To get the latest news on Halberd's exciting developments, including our ongoing PTSD and Alzheimer's Disease eradication accomplishments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com;
support@halberdcorporation.com
http://www.halberdcorporation.com
Twitter:@HalberdC
About Halberd Corporation.
Halberd Corporation (OTC Pink: HALB) is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. It holds the exclusive worldwide rights to several patent- and PCT-pending extracorporeal treatments for COVID-19 and other medical maladies: Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.
https://www.otcmarkets.com/stock/HALB/news/Halberds-VITASHIELDMAXTM-Immunity-Support-Product-Available-on-Amazon?id=323723
No, but your fmyack is. NSAV.
No, you are sleeping. NSAV.
News this week will bring $NSAV$ over 3 C finally.
This volume is not enough to move it. Nice PR should do it. $SBFM$.
Ready for HUGE $SBFM$ NEWS for a long time now!
Good morning and YES! $$$NSAV$$$
MMs manipulation one way or another.
Slowly but surely. $NSAV$
That would be great news indeed. $NSAV$.